`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Art Unit : 1613
`Applicant : James S. Baldassarre et al. (cid:9)
`Examiner : Ernst V. Arnold
`Serial No. : 12/821,020 (cid:9)
`: June 22, 2010 (cid:9)
`Filed (cid:9)
`Conf. No. : 3179
`Title (cid:9)
`: Methods of Reducing the Risk of Occurrence of Pulmonary Edema in Children in
`Need of Treatment with Inhaled Nitric Oxide
`
`SUPPLEMENTAL REMARKS
`
`This application has been granted special status under the prioritized examination
`
`(Track 1) program. An Office action was mailed January 31, 2012, setting a three-month
`
`deadline for response of April 30, 2012. As indicated in the Interview Summary mailed by the
`
`Office on April 24, 2012, the Examiner spoke by telephone with an assistant of the undersigned
`
`on April 20, 2012, stating that the Office action would be replaced with a new Office action.
`
`This message was confirmed by the Examiner in a telephone conference with the undersigned on
`
`April 23, 2012. In addition, the transaction history for this application on PAIR has two entries
`
`dated April 24, 2012: "Mail Notice of Withdrawn Action" and "Withdrawing/Vacating Office
`
`Action Letter." Applicants thus assume that there is no longer a pending deadline for response,
`
`and there will be no deadline for response until the new Office action is mailed and thereby
`
`resets a new deadline.
`
`Applicants filed a Supplemental Amendment on April 30, 2012, with amendments
`
`intended to address potential issues under 35 U.S.C.§ 101 described by SPE Marjorie Moran in a
`
`telephone conference with the undersigned on April 30, 2012. The amendments are based on
`
`SPE Moran's helpful suggestions, so presumably fully address the potential issues described by
`
`her as arising under § 101. Applicants ask that the Supplemental Amendment be entered and
`
`considered prior to preparation of a new Office action.
`
`As noted on page 10 of the Supplemental Amendment, applicants request that SPE Brian
`
`Kwon and QAS Julie Burke continue to participate actively in the prosecution of this application
`
`as a panel with Examiner Arnold. Applicants gratefully note that their perspective on the case
`
`has been very helpful to date in moving the case forward.
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`1
`
`
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`2
`
`
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`3
`
`
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`4
`
`
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`5
`
`
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`6
`
`
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`7
`
`
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`8
`
`
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`9
`
`
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`10
`
`
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`11
`
`
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`12
`
`
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`13
`
`
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`14
`
`
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`15
`
`
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`16
`
`
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`17
`
`
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`18
`
`
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`19
`
`
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`20
`
`
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`21
`
`
`
`IKARIA EXHIBIT 2001
`Praxair v. INO Therapeutics
`IPR2015-00529
`
`22